Back-up generators and secondary manufacturing sites limited the supply and financial impact of Hurricane Maria across J&J’s Puerto Rican pharma facilities, the firm says.
Communication difficulties are hampering drug industry efforts to assess damage to manufacturing operations caused by the hurricane that struck Puerto Rico last week.
DHL Global Forwarding is opening four new temperature-controlled storage chambers in San Juan this year after investing nearly $1m in the market in 2016.
The cold chain solution company, CSafe, has opened a new San Juan-based service center in conjunction with the launch of its new company, CSafe Puerto Rico LLC.
Novartis will close an OTC plant in Puerto Rico by 2019 and transfer manufacturing and packaging actives to sites in the US and facilities operated by Eli Lilly and Virbac.
The Puerto Rico Industrial Development Company (PRIDCO) says Actavis’ investment at two facilities is evidence of continued pharma growth, despite a number of recent closures on the island.
Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
Difficulties transferring know-how from US Pharmas to plants in Puerto Rico may be responsible for the high incidence of manufacturing quality problems on the island, according to the authors of a new study.
The pharmaceutical manufacturing sector in Puerto Rico will thrive because of and not in spite of changes to the country’s tax and incentive laws according to the Puerto Rico Industrial Development Company (PRIDCO).
US healthcare giant Johnson & Johnson (J&J) has recalled 384,000 of its insulin cartridges on concerns the products could cause serious health problems for diabetics.
Bristol-Myers Squibb has recalled 64m tablets of its Avalide blood pressure drug in the US and Puerto Rico over fears it has the potential for reduced efficacy.
Regulations and enforcement were big topics yet again in 2010. in-PharmaTechnologist presents five of our most read on the topics, covering starting material quality and overseas inspections.
The US FDA’s Puerto Rico office may be “having difficulty” monitoring drug manufacturing in the country according to the Congressional Committee on Oversight and Government Reform.
Pfizer plans to close eight manufacturing sites and reduce operations at a further six by the end of 2015, leading to 6,000 job losses, as part of its reorganisation after acquiring Wyeth.
Capacity at Blu Pharmaceutical’s recently acquired solid dosage production plant in Puerto Rico is set to expand considerable over the next three years according to company president Bill Luster.
Patheon says a slowdown in “outsourcing decision making,” manufacturing problems in Puerto Rico and cost related to JLL’s takeover bid hurt it in fiscal 09.
Canadian CMO Patheon will consolidate its Puerto Rican activities at its facility in Manati and sell or close its plant in neighbouring Caguas by 2011.
Patheon has posted “disappointing” Q3 results, with manufacturing difficulties in Puerto Rico, a slowdown in demand for development services and reduced client demand for some products impacting on revenues.
There is still no formal offer on the table for Canadian contract manufacturer Patheon from JLL Patheon Holdings, an investment group which currently owns around 29 per cent of the firm.
DHL Global Forwarding has opened a Life Science Competency Center in Carolina, Puerto Rico, which will offer shipping services tailored to the needs of the island’s biotech and pharmaceutical companies.
UPS is planning on building a new facility in Puerto Rico to help establish a reliable cold-chain delivery service, suggesting a brighter future for the island’s industry.
APP Pharmaceuticals, currently the sole supplier of therapeutic heparin vials to the US market, has received FDA approval to manufacture three new formulations of the blood-thinner at its plant in Barceloneta, Puerto Rico.
Patheon gave an update on its restructuring plans in Puerto Rico
yesterday, saying that its plant in Manati will be updated to
provide contract manufacturing of high-potency drugs and controlled
substances.
Patheon's first quarter results have continued to be impacted by
its underperforming Puerto Rico operations, although restructuring
plans to remedy the situation are in full swing.
Patheon has finally revealed its plans to tackle the ongoing
problems it has been facing with its Puerto Rican operations, which
are draining the firm of profitability.
Puerto Rico is making a concerted effort to attract biologic
investment dollars onto the island as it falls foul of a retreat
from pharma firms seeking solid dose manufacturing.
Pfizer's revelation this week that it plans to slice jobs in Puerto
Rico is the latest in a string of blows for this popular offshore
manufacturing location.
A US bankruptcy court judge ruled on Friday that Puerto Rican-based
pharma services firm Inyx USA be put under the control of an
independently-appointed trustee.
After dismal second quarter results Patheon is stepping up its
resolve for 'damage control' and indicated that further cutbacks at
its problematic Puerto Rico plant are imminent.
